Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sakshi Mattoo"'
Autor:
Anurag Mehta, Himanshi Diwan, Shrinidhi Nathany, Ullas Batra, Manoj Gupta, Manoj Kumar Panigrahi, Dushyant Kumar, Sakshi Mattoo, Aayushi Singh
Publikováno v:
Clinical Pathology, Vol 17 (2024)
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with ROS1 gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners doc
Externí odkaz:
https://doaj.org/article/be6a27af177c40dcb92bcc708e6d85d3
Autor:
Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Amrith BP, Joslia T. Jose, Harkirat Singh, Sakshi Mattoo, Anurag Mehta
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2869-2874 (2023)
Abstract Background KRAS, although a common variant of occurrence (~20% of non‐small‐cell lung carcinoma [NSCLC]) has been untargetable, owing to the molecular structure which inherently prevents drug binding. KRAS mutations in NSCLC are associat
Externí odkaz:
https://doaj.org/article/a5745120cfde4c8db08a5573004aebd2
Autor:
Anurag Mehta, Himanshi Diwan, Diksha Karki, Divya Bansal, Meenakshi Kamboj, Anila Sharma, Shrinidhi Nathany, Sakshi Mattoo, Dushyant Kumar
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 8, Iss , Pp 100205- (2022)
Small Cell Carcinoma of the Ovary-Hypercalcemic Type (SCCOHT) is an aggressive tumor that affects young females, typically in the second decade of life. The patients with SCCOHT harbor somatic or germline mutations in the SMARCA4 gene. Germline mutat
Externí odkaz:
https://doaj.org/article/6a1f6cf61bf3437fbebf26f9dc139f43
Autor:
Anurag Mehta, Shrinidhi Nathany, Aanchal Chopra, Sakshi Mattoo, Dushyant Kumar, Manoj Kumar Panigrahi
Publikováno v:
Journal of Pathology and Translational Medicine, Vol 55, Iss 5, Pp 324-329 (2021)
Background A mutation/deletion involving donor or acceptor sites for exon 14 results in splicing out of exon 14 of the mesenchymal epithelial transition (MET) gene and is known as “MET exon 14 skipping” (ΔMET14). The two recent approvals with su
Externí odkaz:
https://doaj.org/article/d41ab96928f940adad0fc38372c3e87b
Autor:
Ullas Batra, MD, Shrinidhi Nathany, MD, Mansi Sharma, MD, Sakshi Mattoo, MSc, Joslia T. Jose, MTech, Anurag Mehta, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 3, Pp 100286- (2022)
The unprecedented growth of the high-throughput next-generation sequencing has facilitated the identification of rare oncogene fusions such as ROS1 for NSCLC. ROS1 rearrangement has been observed in only 2% of cases of NSCLC and has been successfully
Externí odkaz:
https://doaj.org/article/22de7e19108f4e04bcc81182bf7439c6
Autor:
Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Amrith B. P., Shriya Vaidya, Sakshi Mattoo, Dushyant Kumar, Anurag Mehta
Publikováno v:
South Asian Journal of Cancer, Vol , Iss
Introduction Anaplastic lymphoma kinase (ALK) rearranged non-small cell lung carcinoma (NSCLC) has emerged as a distinct entity with growing number of potent ALK tyrosine kinase inhibitors (TKIs). Despite showing durable responses and promising survi
Externí odkaz:
https://doaj.org/article/3eabcd1fcd7f4690812390b49c47a4e2
Autor:
Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Amrith BP, Joslia T. Jose, Harkirat Singh, Sakshi Mattoo, Anurag Mehta
Publikováno v:
Cancer Medicine. 12:2869-2874
KRAS, although a common variant of occurrence (~20% of non-small-cell lung carcinoma [NSCLC]) has been untargetable, owing to the molecular structure which inherently prevents drug binding. KRAS mutations in NSCLC are associated with distinct clinica
Autor:
Ullas, Batra, Shrinidhi, Nathany, Mansi, Sharma, Sakshi, Mattoo, Anurag, Mehta, Joslia T, Jose
Publikováno v:
Int J Mol Epidemiol Genet
Introduction: Activating mutations in the BRAF gene have been reported in 0.8%-8% cases of NSCLC. Traditionally, diagnostics have mainly focused on detection of V600E and modalities like mutation specific IHC, allele specific real-time PCR have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1178cafdebb9aeaa990de21fc3e9418c
https://europepmc.org/articles/PMC8784904/
https://europepmc.org/articles/PMC8784904/
Publikováno v:
Clinical and experimental medicine. 21(3)
Activating mutations in the KRAS gene (Kirsten rat sarcoma 2 viral oncogene homolog gene) are commonly seen across the various solid organ and hematolymphoid neoplasms. With the likelihood of the mutation specific KRAS inhibitor entering clinical pra
Autor:
Shrinidhi Nathany, Anurag Mehta, Himanshi Diwan, Dushyant Kumar, Sakshi Mattoo, Surender Dhanda, ManojK Panigrahi, Manoj Kumar
Publikováno v:
Journal of Current Oncology. 5:52